Physician profile
Kaissy Hammer
NPI 1275813834
$6,859.78
in general payments reported to CMS, 2019-2025
30 companies · $979 in 2025
The $979 reported for 2025 was more than what 80% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $883 · 2022: $1,640 · 2023: $2,574 · 2024: $785 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,337.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,530.88 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $812.35 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $783.67 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $742.61 | 2021-2023 | |
| Axsome Therapeutics, INC. | $386.63 | 2023 | Auvelity |
| Alexion Pharmaceuticals, INC. | $205.76 | 2023 | Ultomiris |
| Gilead Sciences, INC. | $192.41 | 2024-2025 | Epclusa |
| Astrazeneca Pharmaceuticals Lp | $153.88 | 2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $143.23 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $137.42 | 2022-2023 | Rexulti |
| Braeburn INC. | $128.38 | 2023-2024 | Brixadi |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2023 | Uzedy |
| Calliditas Therapeutics US INC. | $125.00 | 2025 | Tarpeyo |
| Viatris Specialty LLC | $122.10 | 2025 | Yupelri |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $108.40 | 2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $107.35 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $98.23 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $98.09 | 2024 | Cobenfy |
| Edwards Lifesciences Corporation | $95.60 | 2025 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $93.34 | 2024 | Wegovy |
| Neurelis, INC. | $86.57 | 2023 | Valtoco |
| Glaxosmithkline, LLC. | $80.50 | 2022 | |
| Sage Therapeutics, LLC | $79.75 | 2024 | |
| Indivior INC. | $75.46 | 2023-2024 | Sublocade |
| Viiv Healthcare Company | $75.01 | 2021 | |
| Itamar Medical INC | $57.45 | 2023 | Watchpatone |
| Evofem Biosciences, INC. | $49.92 | 2022 | |
| Uswm, LLC | $26.17 | 2024 | Lucemyra |
| Sunovion Pharmaceuticals INC. | $13.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaissy Hammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.